This educational program will explore and analyze data for PCSK9 inhibitor therapeutics in specific patient populations. Expert faculty will relay updates regarding recent PCSK9 inhibitor data and dive into how to optimally apply these therapies into clinical practice. Recent dyslipidemia guidelines will also be reviewed. The panel will discuss how to best improve outcomes for dyslipidemia patients, including those with stroke or at high CV risk.
Cardiologists, internists, nurse practitioners, nurses and other healthcare professionals involved in the management of patients with dyslipidemia
- Explain the most recent subset data for outcomes trials concerning PCSK9 inhibitors
- Apply recent dyslipidemia guidelines and optimal PCSK9 inhibitors into clinical practice
- Incorporate recent PCSK9 inhibitor data to improve outcomes for dyslipidemia patients with stroke or at high CV risk
- Discuss strategies to improve knowledge, skills, or performance of the healthcare team
Alan S. Brown, MD
Director, Division of Cardiology
Advocate Lutheran General Hospital
Park Ridge, Illinois
Past President, American Board of Clinical Lipidology
President, Utah Lipid Center
Salt Lake City, Utah
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, New York
Clinical Pharmacy and Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Alan S. Brown, MD||Consultant/Advisor: Akcea Therapeutics; Amgen Inc.; Kastle Therapeutics; Kowa Pharmaceuticals America, Inc.; Merck; Regeneron PharmaceuticalsSpeaker’s Bureau: Amgen Inc.; Kowa Pharmaceuticals America, Inc.; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLC|
|Eliot A. Brinton, MD||Consultant/Advisor: Akcea Therapeutics; Amarin Pharma Inc.; Balchem; Kowa Pharmaceuticals America, Inc.; Merck; PTS Diagnostics; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLCSpeaker Bureau: Akcea Therapeutics; Amarin Pharma Inc; Boehringer-Ingelheim; Kowa Pharmaceuticals America, Inc.; Merck; Novo Nordisk A/S; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLC|
|Joseph J. Saseen, PharmD, CLS||Nothing to disclose|
|James A. Underberg, MD, MS||Consultant/Advisor: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Invitae Corporation; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLCSpeaker’s Bureau: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLCGrant/Research Support: Aegerion Pharmaceuticals, Inc.; Pfizer|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Gilmartin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hours (1.0 CNE pharmacotherapeutic contact hour).
This activity has been supported by an independent educational grant from Amgen Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Eisai Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CME Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].